Items Tagged ‘Cutaneous Anaplastic Large Cell Lymphoma’

November 15, 2017

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)


-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer of the skin with no known cure and few new treatment options. It is a disfiguring […]

View full entry

Tags: adcetris, brentuximab, Cutaneous Anaplastic Large Cell Lymphoma, mycosis fungoides, News, Non-Hodgkin's Lymphoma, pcALCL, vedotin